Somatostatin receptor imaging for neuroendocrine tumors

Pituitary

Volumn 9, Issue 3, 2006, Pages 243-248

  de Herder, Wouter W ^a   Kwekkeboom, Dik J ^a   Feelders, Richard A ^a   van Aken, Maarten O ^a   Lamberts, Steven W J ^a   van der Lely, Aart Jan ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

111In Pentetreotide; Medullary thyroid carcinoma; Neuroendocrine; Pancreas; Paraganglioma; Pheochromocytoma; Pituitary tumors; Receptor(s); Somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOPEPTIN; FLUORODEOXYGLUCOSE F 18; GADOTERIC ACID; GALLIUM 68; IODINE 123; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ACCURACY; ARTICLE; CANCER STAGING; CARCINOID; DIAGNOSTIC VALUE; GASTRINOMA; HUMAN; HYPOPHYSECTOMY; HYPOPHYSIS TUMOR; IN VIVO STUDY; ISOTOPE LABELING; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PATIENT SELECTION; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; TUMOR RECURRENCE;

ADRENAL GLAND NEOPLASMS; AGED; ANIMALS; CARCINOID TUMOR; CARCINOMA, MEDULLARY; GASTROINTESTINAL NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHEOCHROMOCYTOMA; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 33750998202     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-0270-5     Document Type: Article

References (59)

1. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
2. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47
3. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW (2003) Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10:451-458
4. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC (2005) Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 46(Suppl 1):76S-82S:76S-82S
5. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW (1994) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 733:416-424
6. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
7. Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246-1249
8. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242-244
9. Hubalewska-Dydejczyk A, Szybinski P, Fross-Baron K, Mikolajczak R, Huszno B, Sowa-Staszczak A (2005) (99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: A case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur 8:155-156
10. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 49:237-424
11. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolini I (2005) Image fusion analysis of (99 m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 32:1440-1451
12. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ (2001) Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 42:1134-1138
13. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B (2005) Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 19:311-324
14. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E (2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220:373-380
15. 3 -octreotide: First results in patients with meningiomas. J Nucl Med 42:1053-1056
16. 3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147-157
17. Comaru-Schally AM, Schally AV (2005) A clinical overview of carcinoid tumors: Perspectives for improvement in treatment using peptide analogs. Int J Oncol 26:301-309
18. Lamberts SW, de Herder WW, Hofland LJ (2002) Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451-457
19. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion 55(Suppl 3):54-59
20. Jamar F, Fiasse R, Leners N, Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management. J Nucl Med 36:542-549
21. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511
22. 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762
23. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S-66S
24. 111 In]Octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693
25. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36:1-6
26. de Herder WW, Hofland LJ (2004) Somatostatin receptors in pheochromocytoma. Front Horm Res 31:145-154
27. Kwekkeboom DJ, van Urk H, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP, Krenning EP (1993) Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34:873-878
28. Berna L, Chico A, Matias-Guiu X, Mato E, Catafau A, Alonso C, Mora J, Mauricio D, Rodriguez-Espinosa J, Mari C, Flotats A, Martin JC, Estorch M, Carrio I (1998) Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 25:1482-1488
29. 99m Tc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144:339-345
30. 18 F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: A clinical study and an analysis of the literature. Nucl Med Commun 25:439-443
31. de Herder WW, Lamberts SW (2005) Somatostatin analogs as radiodiagnostic tools. Rev Endocr Metab Disord 6:23-27
32. Kwekkeboom DJ, de Herder WW, Krenning EP (1999) Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 22:80-88
33. 111 In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 39:90-93
34. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362
35. Duet M, Ajzenberg C, Benelhadj S, Lajeunie E, Lormeau B, Guillausseau PJ, Rohmer V, Vilain D, Mundler O, Warnet A (1999) Somatostatin receptor scintigraphy in pituitary adenomas: A somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo. J Nucl Med 40:1252-1256
36. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136:369-376
37. de Herder WW, Kwekkeboom DJ, Reijs AEM et al (1996) Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In: Von Werder K, Fahlbusch R (eds) Pituitary adenomas. From basic research to diagnosis and therapy. Elsevier Science BV, Amsterdam, pp 93-104
38. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M (1997) Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 24:728-731
39. Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G, Ramos C, Riva-Aguilar A (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78:110-115
40. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HA, Bruining HA, Nobels FR (1994) Somatostatin receptor scintigraphy: Its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 96:305-312
41. Weiss M, Yellin A, Husza'r M, Eisenstein Z, Bar-Ziv J, Krausz Y (1994) Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 121:198-199
42. Phlipponneau M, Nocaudie M, Epelbaum J, de Keyzer Y, Lalau JD, Marchandise X, Bertagna X (1994) Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 78:20-24
43. Lefebvre H, Jegou S, Leroux P, Dero M, Vaudry H, Kuhn JM (1995) Characterization of the somatostatin receptor subtype in a bronchial carcinoid tumor responsible for Cushing's syndrome. J Clin Endocrinol Metab 80:1423-1428
44. 111 In-DTPA-D-Phe 1] octreotide. Postgrad Med J 74:108-110
45. Tremble JM, Buxton-Thomas M, Hopkins D, Kane P, Bailey D, Harris PE (2000) Cushing's syndrome associated with a chemodectoma and a carcinoid tumour. Clin Endocrinol (Oxf) 52:789-793
46. Bakalakos EA, Cawley K, O'Dorisio TM, Heck C, Schirmer WJ (1998) Localization of ectopic corticotropin-producing carcinoid tumor with use of indium-111 pentetreotide scintigraphy. Endocr Pract 4:378-381
47. Tsagarakis S, Christoforaki M, Giannopoulou H, Rondogianni F, Housianakou I, Malagari C, Rontogianni D, Bellenis I, Thalassinos N (2003) A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. J Clin Endocrinol Metab 88:4754-4758
48. Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F (1999) Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:1193-1202
49. de Herder WW, Lamberts SW (1999) Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgrad Med J 75:65-66
50. Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK (2004) The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 89:2214-2221
51. Yu J, Koch CA, Patsalides A, Chang R, Altemus RM, Nieman LK, Pacak K (2004) Ectopic Cushing's syndrome caused by an esthesioneuroblastoma. Endocr Pract 10:119-124
52. Jansson JO, Svensson J, Bengtsson BA, Frohman LA, Ahlman H, Wangberg B, Nilsson O, Nilsson M (1998) Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: In vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 48:243-250
53. Greenman Y, Woolf P, Coniglio J, O'Mara R, Pei L, Said JW, Melmed S (1996) Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab 81:1628-1633
54. Moulik PK, Varma TR, Vora JP, Vinjamuri S (2002) The role of somatostatin receptor scintigraphy in the management of pituitary tumours. Nucl Med Commun 23:117-120
55. 111 In-DTPA-octreotide SPET in the detection of minimal post-surgical residues. Nucl Med Commun 19:1127-1134
56. Luyken C, Hildebrandt G, Krisch B, Scheidhauer K, Klug N (1996) Clinical relevance of somatostatin receptor scintigraphy in patients with skull base tumours. Acta Neurochir Suppl (Wien) 65:102-104
57. 111 In-octreotide. Nucl Med Commun 16:756-766
58. Scheidhauer K, Hildebrandt G, Luyken C, Schomacker K, Klug N, Schicha H (1993) Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: First experiences. Horm Metab Res Suppl 27:59-62
59. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675-686